EA201100030A1 - Пиразольные соединения 436 - Google Patents

Пиразольные соединения 436

Info

Publication number
EA201100030A1
EA201100030A1 EA201100030A EA201100030A EA201100030A1 EA 201100030 A1 EA201100030 A1 EA 201100030A1 EA 201100030 A EA201100030 A EA 201100030A EA 201100030 A EA201100030 A EA 201100030A EA 201100030 A1 EA201100030 A1 EA 201100030A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazol compounds
compounds
pyrazol
therapy
contain
Prior art date
Application number
EA201100030A
Other languages
English (en)
Inventor
Дейвид Баттар
Мария-Елена Теоклитоу
Эндрью Питер Томас
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40935715&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100030(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201100030A1 publication Critical patent/EA201100030A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Обеспечиваются новые соединения формулы (Ia) или (Ib)или их фармацевтические соли, способы их получения, фармацевтические композиции, которые их содержат, и их применение в терапии.
EA201100030A 2008-06-19 2009-06-17 Пиразольные соединения 436 EA201100030A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7388308P 2008-06-19 2008-06-19
PCT/GB2009/050684 WO2009153592A1 (en) 2008-06-19 2009-06-17 Pyrazole compounds 436

Publications (1)

Publication Number Publication Date
EA201100030A1 true EA201100030A1 (ru) 2011-08-30

Family

ID=40935715

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100030A EA201100030A1 (ru) 2008-06-19 2009-06-17 Пиразольные соединения 436

Country Status (23)

Country Link
US (1) US20090318468A1 (ru)
EP (1) EP2328872A1 (ru)
JP (1) JP2011524888A (ru)
KR (1) KR20110020904A (ru)
CN (1) CN102123989A (ru)
AR (1) AR072261A1 (ru)
AU (1) AU2009261683A1 (ru)
BR (1) BRPI0914233A2 (ru)
CA (1) CA2728063A1 (ru)
CL (1) CL2010001470A1 (ru)
CO (1) CO6351726A2 (ru)
CR (1) CR11857A (ru)
DO (1) DOP2010000387A (ru)
EA (1) EA201100030A1 (ru)
EC (1) ECSP10010693A (ru)
IL (1) IL210082A0 (ru)
MX (1) MX2010014234A (ru)
PE (1) PE20110062A1 (ru)
SV (1) SV2010003767A (ru)
TW (1) TW201002693A (ru)
UY (1) UY31918A (ru)
WO (1) WO2009153592A1 (ru)
ZA (1) ZA201100471B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US20120258940A1 (en) * 2009-12-18 2012-10-11 Giordano Caponigro Method for treating haematological cancers
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AR090161A1 (es) 2012-02-28 2014-10-22 Astellas Pharma Inc Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AU2014291161B2 (en) 2013-07-18 2018-04-26 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
PL3279202T3 (pl) 2015-03-31 2020-12-28 Taiho Pharmaceutical Co., Ltd. Kryształ 3,5-dipodstawionego związku benzenoalkinylowego
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) * 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7341122B2 (ja) 2017-08-15 2023-09-08 石薬集団中奇制薬技術(石家庄)有限公司 Fgfr阻害剤及びその医薬品の用途
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
MX2020008610A (es) 2018-03-28 2020-09-21 Eisai R&D Man Co Ltd Agente terapeutico para carcinoma hepatocelular.
CN110317173B (zh) * 2018-03-30 2022-10-11 上海奕拓医药科技有限责任公司 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57150846A (en) * 1981-03-13 1982-09-17 Konishiroku Photo Ind Co Ltd Photographic element
JPH0511414A (ja) * 1991-07-02 1993-01-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
CZ290470B6 (cs) * 1991-10-18 2002-07-17 Monsanto Technology Llc 5 či 6 členné aromáty jako fungicidy pro kontrolu stéblolamu rostlin, způsob kontroly a fungicidní směs k provedení tohoto způsobu
HRP921338B1 (en) * 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
JP3419395B2 (ja) * 1999-02-10 2003-06-23 三菱ウェルファーマ株式会社 アミド化合物およびその医薬としての用途
KR20020060160A (ko) * 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
US6552008B1 (en) * 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001290258A1 (en) * 2000-09-22 2002-04-02 Nihon Nohyaku Co. Ltd. N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
JP4224566B2 (ja) * 2000-12-18 2009-02-18 株式会社医薬分子設計研究所 炎症性サイトカイン産生遊離抑制剤
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
JPWO2003103658A1 (ja) * 2002-06-05 2005-10-06 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2003103648A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
WO2003103665A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
US20060004010A1 (en) * 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
WO2004013137A1 (en) * 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7115359B2 (en) * 2003-07-25 2006-10-03 Konica Minolta Medical & Graphic, Inc. Photothermographic material
US7432271B2 (en) * 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
US20050148605A1 (en) * 2003-11-13 2005-07-07 Ambit Biosciences Corporation Amide derivatives as ABL modulators
US7652146B2 (en) * 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof

Also Published As

Publication number Publication date
DOP2010000387A (es) 2012-09-30
AR072261A1 (es) 2010-08-18
TW201002693A (en) 2010-01-16
CR11857A (es) 2011-02-25
WO2009153592A1 (en) 2009-12-23
JP2011524888A (ja) 2011-09-08
BRPI0914233A2 (pt) 2015-11-03
PE20110062A1 (es) 2011-03-09
IL210082A0 (en) 2011-02-28
UY31918A (es) 2010-01-29
ZA201100471B (en) 2012-06-27
ECSP10010693A (es) 2011-01-31
CL2010001470A1 (es) 2011-05-06
MX2010014234A (es) 2011-03-25
EP2328872A1 (en) 2011-06-08
CO6351726A2 (es) 2011-12-20
CN102123989A (zh) 2011-07-13
SV2010003767A (es) 2011-05-20
KR20110020904A (ko) 2011-03-03
AU2009261683A1 (en) 2009-12-23
US20090318468A1 (en) 2009-12-24
CA2728063A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
EA201100030A1 (ru) Пиразольные соединения 436
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
EA200970156A1 (ru) Пиридизиноновые производные
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.